Diarylmethanes through an Unprecedented Palladium-Catalyzed C−C Cross-Coupling of 1-(Aryl)methoxy-1 <i>H</i>-Benzotriazoles with Arylboronic Acids
作者:Manish K. Singh、Mahesh K. Lakshman
DOI:10.1002/cctc.201500818
日期:2015.12
1‐(Aryl)methoxy‐1H‐benzotriazoles (ArCH2OBt) are bench‐stable reagents that are prepared readily from 1H‐benzotriazol‐1‐yl‐4‐methylbenzenesulfonate and benzylic alcohols. These compounds, which contain a N−O−C bond, undergo cross‐coupling with arylboronic acids by C−O bond scission with catalysts that comprise Pd(OAc)2 and biarylphosphine ligands. Such reactivity of ArCH2OBt derivatives, which lead
reaction of aldehydes or ketones through a domino process involving two ensuing steps in a single pot is realized. The compatibility of Matsubara's reagent and Wilkinson's complex give a combination that allows, under dihydrogen, the transformation of a carbonyl function into a methyl group. This new method is suitable to introduce an ethyl motif from aromatic and aliphatic aldehydes with total chemoselectivity
The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.
[EN] INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE<br/>[FR] INHIBITEURS DE PROTÉINES KINASES ASSOCIÉES À RHO (ROCK) ET PROCÉDÉS D'UTILISATION
申请人:H LEE MOFFITT CANCER CT & RES
公开号:WO2013112722A1
公开(公告)日:2013-08-01
Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed.
Novel high affinity thiophene-based and furan-based kinase ligands
申请人:Deng Yongqi
公开号:US20070043045A1
公开(公告)日:2007-02-22
Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.